{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:47:43Z","timestamp":1787014063194,"version":"build-2736575974"},"reference-count":44,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia and Huntington's chorea. Dysphagia, pill aversion, and fear of swallowing are common in patients with these conditions. A new valbenazine sprinkle capsule, to be swallowed whole or the granule contents sprinkled onto soft food, was developed and approved based on the studies presented here. Study 1 evaluated the stability of valbenazine granules in soft foods. Recovery of valbenazine granules within 2\u2009h after addition to applesauce, pudding, and yogurt was 95.6%\u2013100.2%, indicating acceptable stability. Study 2 was a randomized, open\u2010label, 2\u2010cohort, phase 1 study in healthy volunteers. Plasma concentrations of valbenazine and its active metabolite, [+]\u2010\u03b1\u2010dihydrotetrabenazine ([+]\u2010\u03b1\u2010HTBZ) were measured serially after a single dose under various conditions. Cohort 1 evaluated bioequivalence between the sprinkle capsule and the original capsule with compacted powder (reference). Pharmacokinetics of valbenazine and [+]\u2010\u03b1\u2010HTBZ were similar between the whole sprinkle capsule and reference. When granules were sprinkled on applesauce, a lower valbenazine C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC were observed relative to reference; all other parameters were similar. Cohort 2 evaluated food effects on valbenazine granules and found that the pharmacokinetics of valbenazine and [+]\u2010\u03b1\u2010HTBZ were generally similar between fed and fasted states. Overall results from both cohorts for the 90% CIs of the geometric mean ratios indicated bioequivalence between the whole sprinkle capsule or granules sprinkled on applesauce and reference, with minor exceptions. These findings support that the VMAT2 inhibitor valbenazine can be used with multiple modes of oral administration.\n                  <\/jats:p>","DOI":"10.1111\/cts.70390","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:24:54Z","timestamp":1762842294000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0397-0865","authenticated-orcid":false,"given":"Nagdeep","family":"Giri","sequence":"first","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rees","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mar","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bristow","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mello","family":"Hebert","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maynard\u2010Scott","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satjit","family":"Brar","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Neurocrine Biosciences Inc INGREZZA (Valbenazine) Capsules and INGREZZA SPRINKLE (Valbenazine) Capsules. Full Prescribing Information(Neurocrine Biosciences Inc 2025)."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7916\/D88P5Z71"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-013-0222-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-71779-1_1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(85)72863-0"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04265-0"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-022-1743-6"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.58600\/eurjther1914"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1293"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-017-9855-6"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S109285292000200X"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7060067"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-011-9378-5"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99858-w"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318184c905"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000983"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000523"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1577134"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/08964289.2018.1534076"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15463"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9836-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S164406"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2024.03.006"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16137"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-016-0712-3"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-022-10465-x"},{"key":"e_1_2_10_28_1","first-page":"411","article-title":"Medication\u2010Related Swallowing Difficulties May Be More Common Than We Realise","volume":"15","author":"Strachan I.","year":"2005","journal-title":"Pharmacy in Practice"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.7748\/ns.16.42.33.s1"},{"key":"e_1_2_10_30_1","unstructured":"Teva Neuroscience Inc AUSTEDO (Deutetrabenazine) Tablets and AUSTEDO XR (Deutetrabenazine) Extended\u2010Release Tablets. Full Prescribing Information(Teva Neuroscience Inc. 2025)."},{"key":"e_1_2_10_31_1","unstructured":"Pfizer Inc Protonix (Pantoprazole Sodium) Delayed\u2010Release Tablets. Full Prescribing Information(Pfizer Inc 2023)."},{"key":"e_1_2_10_32_1","unstructured":"Bristol Myers Squibb Glucophage (Metformin Hydrochloride) Tablets and Glucophage XR (Metformin Hydrochloride) Tablets. Full Prescribing Information(Bristol Myers Squibb 2017)."},{"key":"e_1_2_10_33_1","unstructured":"AstraZeneca Seroquel XR (Quetiapine) Extended\u2010Release Tablets. Full Prescribing Information(AstraZeneca 2022)."},{"key":"e_1_2_10_34_1","unstructured":"GlaxoSmithKline Wellbutrin (Bupropion Hydrochloride) Tablets. Full Prescribing Information(GlaxoSmithKline 2017)."},{"key":"e_1_2_10_35_1","unstructured":"Eli Lilly and Company Cymbalta (Duloxetine) Delayed\u2010Release Capsules. Full Prescribing Information(Eli Lilly and Co 2023)."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-023-01056-y"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239160"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1205"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.09.024"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9569-4"},{"key":"e_1_2_10_41_1","unstructured":"The U.S. Pharmacopeial Convention \u201cUSP General Chapter <795> Pharmaceutical Compounding\u2014Nonsterile Preparations \u201d(2019)."},{"key":"e_1_2_10_42_1","unstructured":"The U.S. Pharmacopeial Convention \u201cUSP General Chapter <905> Frequently Asked Questions \u201daccessed Sept 25 2025 https:\/\/www.usp.org\/frequently\u2010asked\u2010questions\/uniformity\u2010dosage\u2010units."},{"key":"e_1_2_10_43_1","volume-title":"Food\u2010Effect Bioavailability and Fed Bioequivalence Studies","author":"US Food and Drug Administration","year":"2002"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0202-z"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2022.12.177"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:42:52Z","timestamp":1763980972000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/cts.70390"],"URL":"https:\/\/doi.org\/10.1111\/cts.70390","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70390"}}